Pembrolizumab + Lenvatinib + Carboplatin + Pemetrexed
Phase 2Active 1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-squamous Non-small-cell Lung Cancer
Conditions
Non-squamous Non-small-cell Lung Cancer, EGFR Activating Mutation
Trial Timeline
Jul 1, 2022 → Oct 1, 2024
NCT ID
NCT05258279About Pembrolizumab + Lenvatinib + Carboplatin + Pemetrexed
Pembrolizumab + Lenvatinib + Carboplatin + Pemetrexed is a phase 2 stage product being developed by Merck for Non-squamous Non-small-cell Lung Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05258279. Target conditions include Non-squamous Non-small-cell Lung Cancer, EGFR Activating Mutation.
What happened to similar drugs?
3 of 20 similar drugs in Non-squamous Non-small-cell Lung Cancer were approved
Approved (3) Terminated (1) Active (16)
❌Camrelizumab;Pemetrexed and Carboplatin; Famitinib; + Camrelizumab;Pemetrexed and Carboplatin;PlaceboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05258279 | Phase 2 | Active |
Competing Products
20 competing products in Non-squamous Non-small-cell Lung Cancer